An interventional study of sub-lobectomy and imaging total resection in Glioma and Glioblastoma, sponsored by Huashan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-16.
Sponsored by Huashan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Glioblastoma by Huashan Hospital — 4 open to participants now, 4 under way, none of them phase 3. Glioblastoma · Huashan Hospital.
Among the 10 studies in Glioblastoma by Huashan Hospital, this one is the only one that started in 2024, is one of 2 with no phase, and was the 8th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →4 of the 10 studies in Glioblastoma by Huashan Hospital are open now, in 1 country. Recruiting first, the newest first:
Huashan Hospital · Sites in China
Ages 18+
Huashan Hospital · Sites in China
Ages 18–80
Huashan Hospital
Ages 18–65
By country, each count listing its studies:
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 326 is above the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 45 across the 8 interventional studies, 280 across the 2 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Huashan Hospital is the lead sponsor of 248 studies on the registry; 105 are open to participants now.
2 of the studies in Glioblastoma by Huashan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07538128Huashan HospitalEvaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | 2026-11-27 |
| NCT06368934Huashan HospitalSub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Glioblastoma by Huashan Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Glioblastoma is recognized as the most common and aggressive form of primary malignant brain tumor, with treatment options that are limited and prognosis that is extremely poor, showing median progression-free survival of 12 months and median overall survival of less than 18 months. Surgical resection plays a critical role in the treatment, with the extent of resection significantly impacting patient outcomes. Historical approaches to surgical resection have evolved, moving from radical strategies to more conservative ones that aim to preserve normal brain function while removing the tumor as completely as possible. Recent studies have suggested that increasing the extent of surgical resection, particularly along the T2 FLAIR border rather than the traditional T1-enhanced border, can significantly improve patient prognosis. There is, however, a lack of consensus on the optimal surgical approach, and the heterogeneity of tumors presents challenges in standardizing surgical strategies. Extended resection has been shown to prolong survival, and novel intraoperative molecular diagnostics have emerged to improve accuracy in tumor classification and prognosis. Building on these advancements, a multicenter, prospective, randomized controlled trial is proposed to evaluate the efficacy of sub-lobectomy in treating IDH wild-type/TERTp-mutant glioblastoma, aiming to improve evidence levels and establish standardized surgical practices for this devastating disease.
Glioblastoma is the most prevalent and aggressive type of primary malignant brain tumor[1]. Treatment options are limited and often include surgical resection followed by radiation therapy or electric field therapy[2]. Prognosis is very poor, with median progression-free survival of only 12 months and median overall survival of less than 18 months. The 5-year survival rate is a mere 12% [3].
Surgical resection is fundamental to treating patients with glioblastoma, and the extent of resection directly impacts patient prognosis [4]. Professor William Stewart Halsted, a renowned surgeon, historically championed "radical" surgical resection as a means of controlling tumours [5]. Nevertheless, the majority of neurosurgeons disagreed with this view because of the disruption to normal brain function caused by extreme surgery. However, in 1928, Professor Walter Dandy reported five patients with gliomas who underwent right hemispherectomy [6]. These patients showed no significant neurological impairment except for left hemiparesis. Even though no grave complications arise from the complete resection of the nondominant hemisphere, it did not seem to enhance the patients' prognosis either. Only one out of these five patients survived for 3.5 years, and eventually, all of them passed away due to gliomas. After this, the radical surgical strategy of enlarging the resection margin around gliomas was challenged, and neurosurgeons aimed to achieve total resection of imaging gliomas, based on the principle of removing tumour tissue with an abnormal signal on MRI while preserving normal brain function.
Notably, with respect to the complete surgical removal of glioblastoma, the T1-enhanced borders of MRI imaging were commonly used as a criterion in the past. However, various retrospective studies reveal that increasing the extent of surgical resection significantly improves patient prognosis (median survival from 9.8 to 15.2 months) [7]. However, a recent study conducted retrospectively discovered that resection along the T2 FLAIR border advanced the prognosis of patients with glioblastoma even further compared to resection along the T1 enhancing border (median survival from 11.6 to 31.7 months) [8]. Another study discovered that performing a sub-lobectomy on glioblastoma patients could enhance their prognosis (median survival from 18.7 to 44.1 months) in comparison to T2 FLAIR border resection, as long as normal brain function is not affected [9]. Nonetheless, there remains a lack of consensus in the academic community regarding the optimal surgical resection strategy for glioblastoma patients (such as T1 enhancing border, T2 FLAIR border, sub-lobectomy). In addition, the significant heterogeneity in tumour location, size, infiltration extent, and anatomical proximity across different patients makes it difficult to standardise imaging border resection as an "individualised" surgical approach. This places greater demands on the surgical capabilities and knowledge of clinicians in clinical settings. Furthermore, it also introduces multiple confounding factors that hinder the advancement of interventional clinical research.
Therefore, we have thoroughly reviewed recent studies to investigate the prognosis of glioblastoma patients following extended resection. The majority of studies analyzed the prognostic benefits of extended resection beyond T1 enhancement compared to gross total tumor resection, while a few studies evaluated the difference between sub-lobectomy and gross total tumor resection. Extended resection beyond the T1 enhancement region was discovered to prolong the survival of glioblastoma patients, with the prognostic benefits of sub-lobectomy proving significantly pronounced and not associated with further neurological impairment [9]. Previous studies have several limitations. Firstly, they are predominantly retrospective, leading to issues with selection bias and retrospective memory bias, among other factors. Furthermore, many of these studies lack a balanced control group. Secondly, factors such as a small number of patient cases, short follow-up time, and poor quality control of follow-up have also contributed to their low level of evidence [10]. Furthermore, the classification for glioblastoma were updated in 2021. Patients with gliomas who were included in these studies also await further evaluation to clarify their diagnosis.
Previous studies on the correlation between surgical resection and prognosis of glioblastoma were retrospective due to the absence of molecular pathology. Intraoperative frozen pathology cannot provide real-time diagnosis of glioblastoma. Therefore, molecular testing is crucial for accurate staging and diagnosis. According to the 5th edition of World Health Organization Central Nervous System tumors classification, patients diagnosed with glioblastoma (IDH wild-type) had IDH wild-type adult diffuse glioma accompanied by tissue necrosis, vascular hyperplasia, TERT promoter mutation, +7/-10, or epidermal growth factor receptor (EGFR) amplification [17]. TERT promoter mutation, which is the most frequent hotspot mutation observed in glioblastomas, is present in almost 80% of patients with glioblastoma mutations [18]. We have conducted a range of innovative studies regarding intraoperative rapid integrated diagnosis of gliomas. Our works include ①simplified integrated diagnostic system for human gliomas that is based on a combination of IDH, TERT, and histopathology. ②We have also developed an accurate method for detecting IDH and TERT mutations through the use of locked nucleic acid-amplification refractory mutation system fluorescence polymerase chain reaction (PCR). ③We have optimized the DNA extraction process and reduced the detection cycle as well. ④Conducting multi-center, prospective clinical trials to verify the feasibility of intraoperative rapid molecular testing. In summary, through combining intraoperative frozen pathology, our technique allows for precise diagnosis of glioblastoma (IDH wild-type) with TERT promoter mutations within 35 minutes intraoperatively, with a sensitivity and specificity of 100.0% when compared with postoperative sequencing data. Furthermore, our prior retrospective study found that a higher degree of surgical resection greatly improved the prognosis of glioblastoma with IDH wild-type/TERTp-mutated, and that sub-lobectomy conferred a more significant prognostic benefit.
Therefore, building on previous work and knowledge in our field, we will conduct a multicenter, prospective, randomized controlled trial to evaluate the efficacy of sub-lobectomy in the treatment of IDH wild-type/TERTp-mutant glioblastoma. Our study aims to enhance the level of evidence, while also establishing a standardized surgical strategy for glioblastoma.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
This study's planned enrollment of 326 is above the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Browse Glioblastoma studies →Huashan Hospital is the lead sponsor of 248 studies on the registry; 105 are open to participants now.
Compared within Glioblastoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glioma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention group was to receive frontal, temporal, parietal, and occipital sub-lobotomies that met anatomical criteria.
Procedure: sub-lobectomy
The control group was to receive imaging total resection (T1-enhanced borders) that met RANO criteria.
Procedure: imaging total resection
Combined with previous research and our team's precise neurosurgery concept, we define the surgical strategy based on lobectomy and further preserving the brain parenchyma in functional areas according to anatomical landmarks and electrophysiological boundaries as sub-lobectomy.
Imaging total resection (T1-enhanced borders) will met the RANO criteria
Progression-free Survival
Progression-free Survival (PFS) in patients with IDH wild-type/TERTp-mutant glioblastoma in the sub-lobectomy group and in the imaging total resection (T1-enhanced border) group.
Time frame: From date of randomization until the date of first documented progression, assessed up to 36 months
Overall Survival
Overall Survival (OS) in patients with IDH wild-type/TERTp-mutant glioblastoma in the sub-lobectomy group and in the imaging total resection (T1-enhanced border) group.
Time frame: From date of randomization until the date of death from any cause, assessed up to 36 months
Postoperative quality of life
Using Karnofsky Performance Scale (KPS) to evaluate for postoperative quality of life.
Time frame: up to 6 months
Adverse effects
The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) scale was used to assess adverse effects.
Time frame: up to 6 months
Cognitive function
The cognitive function will be assessed by Mini-mental State Examination (MMSE) scale.
Time frame: up to 3 months
Language function
The language function will be assessed by aphasia examination of chinese.
Time frame: up to 3 months
Limb muscle strength
The limb muscle strength will be assessed by Manual Muscle Test (MMT).
Time frame: up to 3 months
Plan to share: Undecided
Start is estimated for Apr 2024; primary completion for Dec 2026, 32 months later.
Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 32 months is below that.
Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.